NASDAQ$ORIC
ORIC Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
ORIC Pharmaceuticals reported financial results and operational updates for Q2 2021.
ORIC Pharmaceuticals reported its Q2 2021 financial results, highlighting the initial data readout for ORIC-101 in combination with nab-paclitaxel and the FDA clearance of the IND application for ORIC-533. The company's cash and investments totaled $305.9 million, expected to fund operations into 2024.
- Initial ORIC-101 clinical data was presented at ASCO.
- ORIC-533 IND was cleared by the FDA.
- Preclinical data was presented at AACR.
- The company raised gross proceeds of $50.0 million through the sale of approximately 2.6 million shares under its ATM offering.
Headline financials
Revenue & EPS history
ORIC Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
ORIC anticipates several milestones in the second half of 2021 related to its clinical programs.
Tailwinds
- Report interim data from ORIC-101 combination trial with enzalutamide.
- Initiate Phase 1 study for ORIC-533.
- File IND for ORIC-944.
- File CTA for ORIC-114.
- Present additional preclinical data at scientific conferences.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.2%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+8.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+14.7%
Q2 2023
Best reaction
-29.8%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +14.7% | +14.9% | +5.7% | |
| Q3 2025 | +0.3% | -5.8% | -23.1% | |
| Q2 2025 | -1.0% | -7.9% | +8.9% | |
| Q1 2025 | +8.7% | +25.8% | +98.9% | |
| Q4 2024 | +0.8% | +2.1% | -43.5% | |
| Q3 2024 | -0.3% | -17.5% | -18.2% | |
| Q1 2024 | -1.0% | -7.4% | -5.6% | |
| Q4 2023 | -4.5% | +0.7% | -33.3% | |
| Q3 2023 | -3.2% | -11.9% | +26.4% | |
| Q2 2023 | +14.7% | +13.8% | +17.3% | |
| Q1 2023 | -0.4% | +0.1% | +11.4% | |
| Q4 2022 | +5.3% | +14.8% | +39.5% | |
| Q3 2022 | +2.8% | +17.9% | +35.4% | |
| Q2 2022 | +3.2% | -2.1% | -26.4% | |
| Q1 2022 | -3.4% | -4.4% | +52.0% | |
| Q4 2021 | -29.8% | -33.0% | -42.6% | |
| Q3 2021 | +7.1% | +8.4% | -7.1% | |
| Q2 2021 | +9.4% | +13.6% | +45.2% | |
| Q1 2021 | +2.1% | +6.1% | -17.0% | |
| Q4 2020 | -6.2% | -7.6% | -10.2% | |
| Q3 2020 | +3.8% | +4.4% | +55.6% | |
| Q2 2020 | +12.5% | +12.4% | +7.8% | |
| Q1 2020 | -8.7% | -11.3% | +7.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro